“…In the rat ileum, the mRNAs of both cannabinoid receptors and their expression have been both identified and mapped in the myenteric plexus Valenti et al, 2005;Duncan et al, 2008). Furthermore, a number of endogenous cannabinoid ligands, exemplified by arachidonylethanolamide (AEA) and 2-arachidonylglycerol (2-AG), (Gomez et al, 2002;Mascolo et al, 2002;Izzo et al, 2003;Fegley et al, 2005;Valenti et al, 2005), along with the mechanisms for their enzymatic inactivation (Katayama et al, 1997), have been shown to be present in the rat ileum. Therefore, the purpose of this study was to investigate whether the rat ileum myenteric plexuslongitudinal muscle (MPLM) preparation served as a suitable and robust in vitro ileal cannabinoid receptor bioassay by assessing the interaction between representatives of the four main classes of cannabinoid receptor agonists, that is AEA, 5-(1,1-dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)-cy clohexyl]-phenol (CP 55,940), D 9 -tetrahydrocannabinol (D 9 -THC) and (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinyl methyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalen ylmethanone mesylate (WIN 55,, with the CB1 and CB2 receptor selective antagonist /inverse agonists rimonabant and SR 144 528 respectively.…”